Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Andy Ni"'
Autor:
Anne L. Loeser, Lucy Gao, Aditya Bardia, Mark E. Burkard, Kevin M. Kalinsky, Jeffrey Peppercorn, Hope S. Rugo, Martha Carlson, Janice Cowden, Lesley Glenn, Julia Maues, Sheila McGlown, Andy Ni, Natalia Padron, Maryam Lustberg
Publikováno v:
Breast Cancer Research and Treatment. 196:549-563
Although metastatic breast cancer (MBC) is treatable, it is not curable and most patients remain on treatment indefinitely. While oncologists commonly prescribe the recommended starting dose (RSD) from the FDA-approved label, patient tolerance may di
Autor:
Qun-Ying Hu, Paola Ghione, Ahmet Dogan, Peter G. Cordeiro, Natasha Galasso, Steven M. Horwitz, Andy Ni, Nivetha Ganesan
Publikováno v:
J Plast Reconstr Aesthet Surg
Summary Background The risk of BIA-ALCL for patients with textured breast implants has been estimated between 1/2832 and 1/30,000 women. Existing studies estimating the numbers exposed and at risk, may have under reported cases, and/or lacked compreh
Autor:
Helena A. Yu, Michael F. Berger, Andy Ni, Gregory J. Riely, Maria E. Arcila, Hyunjae R. Kim, Francisco Sanchez-Vega, Marc Ladanyi, Charles M. Rudin, Kathryn C. Arbour, Matthew D. Hellmann, Mark G. Kris, Jordan Dienstag, David B. Solit, Piro Lito, Emmet Jordan
Publikováno v:
Clinical Cancer Research. 24:334-340
Purpose: KRAS mutations occur in approximately 25% of patients with non–small cell lung cancer (NSCLC). Despite the uniform presence of KRAS mutations, patients with KRAS-mutant NSCLC can have a heterogeneous clinical course. As the pattern of co-o
Autor:
Martine van Voorthuysen, Andrew J. Plodkowski, Lu Wang, Michelle S. Ginsberg, Maria E. Arcila, Andy Ni, Joseph Montecalvo, Alexander Drilon, Romel Somwar, Natasha Rekhtman, Gregory J. Riely, Marc Ladanyi, Mark G. Kris, Charles M. Rudin, Melanie Albano, Roger S. Smith
Publikováno v:
The Lancet. Oncology
Summary Background RET rearrangements are found in 1–2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the a
Autor:
Andy Ni, Andrea Cercek, Marjorie G. Zauderer, Liying Zhang, Prasad S. Adusumilli, Alexander N. Shoushtari, Sandra P. D'Angelo, Garrett M. Nash, Mariel A. DuBoff, Beth Siegel, Paul B. Chapman, Jasmine H. Francis, Angela G. Arnold, Mark E. Robson, Andreas Rimner, William D. Travis, Gowtham Jayakumaran, David H. Abramson, Jennifer L. Sauter, Megan Harlan Fleischut, Valerie W. Rusch, Marc Ladanyi, Diana Mandelker, Ahmet Zehir
Publikováno v:
J Thorac Oncol
Introduction Inherited mutations are easily detected factors that influence the disease courses and optimal treatment strategies of some cancers. Germline mutations in BRCA1 associated protein 1 (BAP1) are associated with unique disease profiles in m
Autor:
Carol S. Portlock, Anas Younes, Steven M. Horwitz, Ahmet Dogan, Maria Lia Palomba, David J. Straus, Connie Lee Batlevi, Matthew J. Matasar, Alison J. Moskowitz, Fushen Sha, Anita Kumar, Paul A. Hamlin, Ahmed Toure, Andrew D. Zelenetz, Ariela Noy, Craig H. Moskowitz, Andy Ni
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 6, Pp 1-10 (2019)
Blood Cancer Journal, Vol 9, Iss 6, Pp 1-10 (2019)
As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients are increasingly being treated with multiple regimens. However, outcome after each line remains poorly characterized in the modern era. To address this knowled
Autor:
Julia Dai, Jinah Kim, Steven M. Horwitz, Alison J. Moskowitz, Meenal Kheterpal, Patricia L. Myskowski, Richard T. Hoppe, Sophia Fong, Melissa Pulitzer, E. Hong, Shamir Geller, Youn H. Kim, Andy Ni
Publikováno v:
J Am Acad Dermatol
Background Whole-body imaging is the current standard of care for staging all patients presenting with skin lesions of B-cell lymphomas (BCLs), regardless of skin disease extent; however, supporting data are lacking. Objective To determine the clinic
Autor:
David Planchard, Niamh Long, W. Victoria Lai, Andrew J. Plodkowski, Kathryn C. Arbour, Matthew D. Hellmann, Roberto Ferrara, Benjamin Besse, Edouard Auclin, Laura Mezquita, Joshua K. Sabari, Darragh Halpenny, Jamie E. Chaft, Lizza E.L. Hendriks, Gregory J. Riely, Caroline Caramella, Hira Rizvi, Gala Martínez-Bernal, Andy Ni
Publikováno v:
Journal of Clinical Oncology, 36(28), 2872-2878. American Society of Clinical Oncology
Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy of PD-(L)1 blockade. On-treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a2ccbb41f385e6e73e807d4d93c1c5
https://hdl.handle.net/10668/12856
https://hdl.handle.net/10668/12856
Autor:
Andy Ni, Joachim Yahalom, Matthew J. Matasar, Joanna C. Yang, Paul A. Hamlin, Andrew D. Zelenetz, Craig H. Moskowitz, Santosha Vardhana, Craig S. Sauter
Publikováno v:
Biol Blood Marrow Transplant
Primary mediastinal (thymic) large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma with distinct clinical, molecular and genetic features, many of which overlap with Hodgkin’s lymphoma. Increasingly, initial therapy for these patients
Autor:
Elizabeth Panora, Matthew D. Hellmann, Mario E. Lacouture, Charles M. Rudin, Andrew J. Plodkowski, Maya Gambarin-Gelwan, Hira Rizvi, Darragh Halpenny, Andy Ni, Olivia Wilkins, Mark G. Kris, Niamh Long, Jamie E. Chaft, Fernando C. Santini
Publikováno v:
Cancer immunology research. 6(9)
Considering retreatment following recovery from an immune-related adverse event (irAE) is a common clinical scenario, but the safety and benefit of retreatment is unknown. We identified patients with advanced non–small cell lung cancer (NSCLC) trea